A Study to Assess the Safety and Efficacy of 7 Days Treatment With a Novel Analgesic in Subjects With Peripheral Neuropathic Pain

NCT01485094 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

114

Enrollment

INDUSTRY

Sponsor class

Stopped The trial was early terminated after it was concluded that there was no added benefit from exposing further participants after an unblinded interim analysis.

Conditions

Neuralgia

Interventions

DRUG: GRT6010
DRUG: Pregabalin
DRUG: Matching Placebo

Sponsor

Grünenthal GmbH